The Stage trial of Merck recombinant adenovirus type 5 HIV-1 vaccine including subtype B gag, pol, and nef in high-risk men who’ve sex with men was stopped because of futility and perhaps higher rates of disease in vaccine recipients.37 An immunologic correlate with protection from HIV-1 infection is not determined at this time.12 The vaccines that were found in our trial demonstrated an even of immunogenicity that was much like levels reported previously.17 Additional studies with the use of more recently developed immunogenicity assays are prepared in order to determine their suitability for correlates analyses.38-41 Further insight might be gained through molecular-sieve analysis of breakthrough infections by using single-genome amplification.42 Although our study supplied preliminary evidence an HIV vaccine regimen has the potential to prevent infection, it did not have the power to handle two intriguing considerations: vaccine efficacy may have decreased over the first year after vaccination, and vaccine efficacy may have been greater in persons at lower risk for infection .Out this week, for example, are papers on what ACOs are paid and on tying payment to the right kind of quality performance standards. The papers are made to be sure that the teams of providers who constitute ACOs aren’t rewarded simply for decreasing spending . This content was reprinted from with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an editorially independent news service, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente..